Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder.

Saved in:
Bibliographic Details
Title: Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder.
Authors: Geuze, E, van Berckel, B N M, Lammertsma, A A, Boellaard, R, de Kloet, C S, Vermetten, E, Westenberg, H G M
Source: Molecular Psychiatry. Jan2008, Vol. 13 Issue 1, p74-83. 10p. 1 Color Photograph, 3 Charts.
Subjects: Aminobutyric acid, Drug receptors, Nervous system, Psychological stress, Central nervous system
Abstract: γ-Aminobutyric acid (GABAA) receptors are thought to play an important role in modulating the central nervous system in response to stress. Animal data have shown alterations in the GABAA receptor complex by uncontrollable stressors. SPECT imaging with benzodiazepine ligands showed lower distribution volumes of the benzodiazepine-GABAA receptor in the prefrontal cortex of patients with post-traumatic stress disorder (PTSD) in one, but not in another study. The objective of the present study was to assess differences in the benzodiazepine-GABAA receptor complex in veterans with and without PTSD using [11C]flumazenil and positron emission tomography (PET). Nine drug naive male Dutch veterans with deployment related PTSD and seven male Dutch veterans without PTSD were recruited, and matched for age, region and year of deployment. Each subject received a [11C]flumazenil PET scan and a structural magnetic resonance imaging scan. Dynamic 3D PET scans with a total duration of 60 min were acquired, and binding in template based and manually defined regions of interest (ROI) was quantified using validated plasma input and reference tissue models. In addition, parametric binding potential images were compared on a voxel-by-voxel basis using statistical parametric mapping (SPM2). ROI analyses using both template based and manual ROIs showed significantly reduced [11C]flumazenil binding in PTSD subjects throughout the cortex, hippocampus and thalamus. SPM analysis confirmed these results. The observed global reduction of [11C]flumazenil binding in patients with PTSD provides circumstantial evidence for the role of the benzodiazepine-GABAA receptor in the pathophysiology of PTSD and is consistent with previous animal research and clinical psychopharmacological studies.Molecular Psychiatry (2008) 13, 74–83; doi:10.1038/sj.mp.4002054; published online 31 July 2007 [ABSTRACT FROM AUTHOR]
Copyright of Molecular Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:γ-Aminobutyric acid (GABAA) receptors are thought to play an important role in modulating the central nervous system in response to stress. Animal data have shown alterations in the GABAA receptor complex by uncontrollable stressors. SPECT imaging with benzodiazepine ligands showed lower distribution volumes of the benzodiazepine-GABAA receptor in the prefrontal cortex of patients with post-traumatic stress disorder (PTSD) in one, but not in another study. The objective of the present study was to assess differences in the benzodiazepine-GABAA receptor complex in veterans with and without PTSD using [11C]flumazenil and positron emission tomography (PET). Nine drug naive male Dutch veterans with deployment related PTSD and seven male Dutch veterans without PTSD were recruited, and matched for age, region and year of deployment. Each subject received a [11C]flumazenil PET scan and a structural magnetic resonance imaging scan. Dynamic 3D PET scans with a total duration of 60 min were acquired, and binding in template based and manually defined regions of interest (ROI) was quantified using validated plasma input and reference tissue models. In addition, parametric binding potential images were compared on a voxel-by-voxel basis using statistical parametric mapping (SPM2). ROI analyses using both template based and manual ROIs showed significantly reduced [11C]flumazenil binding in PTSD subjects throughout the cortex, hippocampus and thalamus. SPM analysis confirmed these results. The observed global reduction of [11C]flumazenil binding in patients with PTSD provides circumstantial evidence for the role of the benzodiazepine-GABAA receptor in the pathophysiology of PTSD and is consistent with previous animal research and clinical psychopharmacological studies.Molecular Psychiatry (2008) 13, 74–83; doi:10.1038/sj.mp.4002054; published online 31 July 2007 [ABSTRACT FROM AUTHOR]
ISSN:13594184
DOI:10.1038/sj.mp.4002054